



**Table 1.** Distribution of Different SARS-CoV-2 Lineages Identified in the Brazilian States

Region	State	SARS-CoV-2 Lineages	Total
North	Acre	B.1.1, B.1.1.33, B.1.212	3
	Amapá	B.1.1.33, B.1.160.25, N.10, P.1, P.2	5
	Amazonas	A.2, B.1, B.1.1, B.1.1.117, B.1.1.218, B.1.1.28, B.1.1.33, B.1.1.34, B.1.1.378, B.1.111, B.1.195, B.1.212, B.1.319, B.1.566, N.9, P.1, P.1.1, P.2	18
	Pará	B.1, B.1.1, B.1.1.1, B.1.1.28, B.1.1.33, B.1.212, B.1.395, B.39, N.9, P.1, P.2	11
	Rondônia	B.1.1.28, B.1.1.33, B.1.212, N.9, P.1, P.2	6
	Roraima	B.1, B.1.1.33, P.1	3
	Tocantins	B.1, B.1.1, B.1.1.28, B.1.1.33, P.1, P.2	6
Northeast	Alagoas	B.1.1, B.1.1.143, B.1.1.28, B.1.1.29, B.1.1.33, B.1.1.34, B.1.1.371, B.1.1.372, B.1.1.7, N.9, P.1, P.2	12
	Bahia	A.1, B.1, B.1.1, B.1.1.106, B.1.1.141, B.1.1.162, B.1.1.180, B.1.1.28, B.1.1.29, B.1.1.314, B.1.1.33, B.1.1.333, B.1.1.34, B.1.1.7, B.1.167, B.1.525, B.1.610, B.3, C.14, N.4, N.9, P.1, P.2	20
	Ceará	B, B.1, B.1.1, B.1.1.143, B.1.1.28, B.1.1.282, B.1.1.33, B.1.1.34, B.1.1.44, B.1.212, N.9, P.1, P.2	13
	Maranhão	B.1.1, B.1.1.28, B.1.1.33, B.1.1.332, B.1.234, N.10, N.9, P.1, P.2	9
	Paraíba	B.1, B.1.1, B.1.1.141, B.1.1.143, B.1.1.232, B.1.1.269, B.1.1.28, B.1.1.29, B.1.1.33, B.1.1.34, B.1.1.462, B.1.212, N.9, P.1, P.2	15
	Pernambuco	B, B.1, B.1.1, B.1.1.10, B.1.1.117, B.1.1.139, B.1.1.15, B.1.1.192, B.1.1.28, B.1.1.29, B.1.1.208, B.1.1.227, B.1.1.314, B.1.1.33, B.1.1.34, B.1.1.74, B.1.1.94, B.1.212, B.1.258, N.9, P.2	21
	Piauí	B.1.1.33, N.9	2
	Rio Grande do Norte	B.1.1, B.1.1.28, B.1.1.33, B.1.195, N.9, P.1, P.2	7
	Sergipe	B.1, B.1.1, B.1.1.28, B.1.1.29, B.1.1.33, B.1.1.7, B.1.212, B.1.610, B.59, N.9, P.1, P.2	12
Mid West	Distrito Federal	B, B.1, B.1.1, B.1.1.28, B.1.1.33, B.1.1.7, B.1.177.32, P.1, P.2	9
	Goiás	B.1, B.1.1.28, B.1.1.29, B.1.1.33, B.1.1.7, B.1.22, B.40, P.1, P.2	9
	Mato Grosso	B.1.1.28, B.1.1.33, B.1.1.7, B.4	4
	Mato Grosso do Sul	B.1, B.1.1, B.1.1.28, B.1.1.33, B.1.1.7, B.1.212, B.1.240, B.1.547, N.4, P.1, P.2	11
Southeast	Espírito Santo	B.1, B.1.1, B.1.1.143, B.1.1.28, B.1.1.33, B.1.1.7, B.40, P.1, P.2	9
	Minas Gerais	B, B.1, B.1.1, B.1.1.143, B.1.1.190, B.1.1.218, B.1.1.28, B.1.1.33, B.1.1.372, B.1.1.7, B.1.1.71, B.1.153, B.1.177, B.1.2, B.1.212, B.1.234, B.1.235, B.1.314, B.1.36.10, B.1.408, B.1.526.1, B.1.9, B.59, B.61, P.1, P.2	26
	Rio de Janeiro	A.2, B.1, B.1.1, B.1.1.109, B.1.1.143, B.1.1.218, B.1.1.222, B.1.1.277, B.1.1.28, B.1.1.29, B.1.1.306, B.1.1.31, B.1.1.314, B.1.1.33, B.1.1.393, B.1.1.7, B.1.1.94, B.1.111, B.1.153, B.1.167, B.1.222, B.1.398, B.1.422, B.1.565, B.1.577, B.1.582, B.1.596, B.39, N.1, N.4, N.9, P.1, P.2	33
	São Paulo	A, B, B.1, B.1.1, B.1.1.1, B.1.1.143, B.1.1.208, B.1.1.28, B.1.1.318, B.1.1.33, B.1.1.332, B.1.1.333, B.1.1.378, B.1.1.393, B.1.1.464, B.1.1.519, B.1.1.7, B.1.177.52, B.1.195, B.1.212, B.1.221, B.1.234, B.1.351, B.1.446, B.1.566, B.23, B.3, B.40, B.6, N.9, P.1, P.1.1, P.2	33
South	Paraná	A, B.1, B.1.1, B.1.1.1, B.1.1.143, B.1.1.250, B.1.1.28, B.1.1.29, B.1.1.33, B.1.1.7, B.1.195, B.1.375, B.1.498, B.1.98, P.1, P.1.1, P.2	17
	Rio Grande do Sul	A, B, B.1, B.1.1, B.1.1.143, B.1.1.28, B.1.1.29, B.1.1.33, B.1.1.332, B.1.1.7, B.1.1.70, B.1.177, B.1.195, B.1.212, B.1.416, B.1.575, B.1.91, P.1, P.2	19
	Santa Catarina	B.1, B.1.1, B.1.1.1, B.1.1.143, B.1.1.279, B.1.1.28, B.1.1.33, B.1.1.332, B.1.1.7, B.1.195, B.6, N.9, P.1, P.2	14

syndrome (MIS-C), a life-threatening disease, similar to toxic shock syndrome and Kawasaki disease. MIS-C is predominantly reported among children of Black and/or Latino ancestry. Thus, schools reopening in Africa and Latin America countries may generate epidemic patterns that differ from those on other continents, especially during the high local circulation of SARS-CoV-2. For example, more transmissible variants have emerged in Brazil (P.1 lineage) and South Africa (B.1.351 lineage).<sup>4,6</sup>

In 2020, researchers verified high rates of SARS-CoV-2 infection by B.1.195 and B.1.1.28 lineages, with subsequent seroconversion in the population of Manaus, Brazil. However, the P.1 lineage, a variant with mutations related to increased

transmissibility, ACE-2 affinity, and antibody evasion, resulted in outbreaks and COVID-19 recurrence in Manaus during January 2021, spreading throughout the country thereafter, including municipalities bordering Peru, Colombia, and Venezuela. Hence, the genetic, immunological, and epidemiological characteristics of new SARS-CoV-2 lineages should be monitored regionally, and the clinical risk for new patients should be assessed, especially in grouping situations, such as children in classrooms.<sup>7</sup> The emergence and dissemination of new variants occur due to epidemiological factors, such as the lack of efficient social distancing, contributing to the occurrence of pediatric outbreaks, increased hospitalizations and bed occupations.<sup>6,7</sup> Recently, the Oswaldo

Cruz Foundation (FIOCRUZ) Genomics Network reported the presence of 110 SARS-CoV-2 lineages in Brazilian states, including highly transmissible lineages related to outbreaks and more severe cases of COVID-19. This finding reinforces the genomic surveillance need to properly manage the COVID-19 pandemic in Brazil (Table 1).<sup>8</sup>

The ethnic diversity and socioeconomic inequalities present in Brazil also determine the epidemiology of COVID-19. Although studies performed in developed countries have determined that the spread and worsening of COVID-19 among children have low significance, regional differences have been observed among Brazilian children and adolescents with COVID-19 such as higher mortality in less socioeconomically developed municipalities, especially in the northern region of Brazil. Furthermore, individuals with 2 or more comorbidities may have 9.6-fold increased risk of death from COVID-19.<sup>4,9</sup> Another Brazilian study analyzed patients aged <19 years infected with SARS-CoV-2 in the state of Sergipe, Northeastern Brazil, and verified that the mortality rate was 37-fold higher than that reported in the United States and the United Kingdom. This unusual and high mortality rate increases with the local absence of pediatric intensive care unit (ICU) beds and the presence of comorbidities, such as neurological diseases and prematurity.<sup>10</sup> To avoid COVID-19 and subsequent pediatric hospitalizations with the return of face-to-face classes, appropriate mitigation measures are necessary.

The main strategies in health protocols for preventing the COVID-19 spread in face-to-face classes are mask wearing, sanitization of hands, surface disinfection, guidance for home quarantine of students or employees with a positive test for SARS-CoV-2, and adjustment of infrastructure in schools.<sup>4</sup> On the other hand, the scarce resources invested in Brazilian public education in recent years have placed these educational institutions in very precarious conditions, increasing social inequalities. The average amount spent per student in Brazil is half that spent by Brazilian private schools and countries of the Organization for Economic Co-operation and Development (OECD). In addition, the adverse economic effects caused by the COVID-19 pandemic have also resulted in reduced resources for basic education, as seen in countries with an educational financing system similar to the Brazilian system. Thus, the lack of basic infrastructure in Brazilian public schools represents an obstacle to the necessary adaptations to prevent the spread of SARS-CoV-2 among students and staff.<sup>2</sup>

Therefore, the elaboration and execution of health protocols for the schools reopening during the pandemic should be supported by

real data representative of each region and Brazilian context because socioeconomic vulnerabilities and comorbidities are risk factors for the worsening of COVID-19 rates among Brazilian children. As long as no COVID-19 vaccination or treatment is available for children, the return to face-to-face classes places Brazilian students at higher risk for COVID-19 due to the national circulation of highly transmissible SARS-CoV-2 lineages and the lack of hospital beds in low-income regions of the country.

#### Acknowledgments.

**Financial support.** This study was supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior of Brazil (CAPES; finance code 001).

**Conflicts of interest.** All authors report no conflicts of interest relevant to this article.

#### References

1. Tang S, Xiang M, Cheung T, Xiang YT. Mental health and its correlates among children and adolescents during COVID-19 school closure: the importance of parent-child discussion. *J Affect Disord* 2021;279:353–360.
2. Alves T, Farenzena N, Silveira AAD, Pinto JMDR. Implications of the COVID-19 pandemic on funding basic education. *Rev de Adm Pública* 2020;54:979–993.
3. COVID-19 impact on education. Global monitoring of school closures. UNESCO website. <https://en.unesco.org/covid19/educationresponse>. Accessed May 31, 2021.
4. Esposito S, Zona S, Vergine G, *et al.* How to manage children if a second wave of COVID-19 occurs. *Int J Tuberc Lung Dis* 2020;24:1116–1118.
5. Lee B, Raszka WV. COVID-19 in children: looking forward, not back. *Pediatrics* 2021;147:e2020029736.
6. Parcha V, Booker KS, Kalra R, Kuranz S, Berra L, Arora G, Arora P. A retrospective cohort study of 12,306 pediatric COVID-19 patients in the United States. *Sci Rep* 2021;11:1–10.
7. Naveca FG, Nascimento V, de Souza VC. COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P. 1 emergence. *Nat Med* 2021. doi: 10.1038/s41591-021-01378-7.
8. Tabelas de dados demonstrativos de linhagens e genomas SARS-CoV-2. FIOCRUZ Genomics Network website. <http://www.genomahcov.fiocruz.br/tabela-de-dados/>. Accessed May 31, 2021.
9. Sousa BLA, Brentani AVM, Ribeiro CCC, *et al.* Noncommunicable diseases, sociodemographic vulnerability, and the risk of mortality in hospitalized children and adolescents with COVID-19 in Brazil: a syndemic in play. *medRxiv* 2021. doi: 10.1101/2021.02.11.21251591.
10. Lopes ASA, Vieira SCF, Porto RLS, *et al.* Coronavirus disease-19 deaths among children and adolescents in an area of Northeast Brazil: why so many? *Trop Med Int Health* 2021;26:115–119.